Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Company Deals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Fineline Cube Jul 15, 2026
Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Fineline Cube Jul 15, 2026
Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Fineline Cube Jul 15, 2026
Company Drug

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...

Medical Device

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Fineline Cube Sep 23, 2025

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085) announced that its affiliate Agloe Medical Technologies has...

Company Drug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Fineline Cube Sep 23, 2025

Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...

Company Deals Drug

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Fineline Cube Sep 23, 2025

Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...

Company Drug

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

Fineline Cube Sep 23, 2025

Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Fineline Cube Sep 23, 2025

The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...

Company Drug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Fineline Cube Sep 23, 2025

Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration...

Company Drug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Fineline Cube Sep 23, 2025

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...

Company Drug

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

Fineline Cube Sep 23, 2025

Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...

Company Drug

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Fineline Cube Sep 23, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the first patient has been dosed in Australia...

Company Drug

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

Fineline Cube Sep 23, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug...

Company Deals

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration

Fineline Cube Sep 22, 2025

Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...

Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Fineline Cube Sep 22, 2025

The National Healthcare Security Administration (NHSA) announced today that the expert review for the 2025...

Company Drug

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic

Fineline Cube Sep 22, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug...

Company Deals

Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development

Fineline Cube Sep 22, 2025

Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts‑based Alcyone Therapeutics. The deal centers on...

Company Drug

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars

Fineline Cube Sep 22, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Commission...

Company Drug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

Fineline Cube Sep 22, 2025

Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...

Company Deals

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

Fineline Cube Sep 22, 2025

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed...

Company Deals

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party

Fineline Cube Sep 22, 2025

Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back...

Company Drug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Fineline Cube Sep 19, 2025

Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 129 130 131 … 695

Recent updates

  • Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
  • Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
  • Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
  • Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
  • Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.